Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03731260 Phase II Avapritinib (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent and Smoldering Systemic Mastocytosis Active, not recruiting USA | SWE | NOR | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BEL 0
NCT04333108 Phase III Masitinib Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment Recruiting ROU | POL | NLD | GBR | FRA | DEU 2
NCT04655118 Phase II TL-895 Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis Recruiting USA | POL | ITA | HUN | FRA | ESP | DEU | BRA | BGR | BEL | AUS 2
NCT04910685 Phase II Elenestinib (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis Recruiting USA | NOR | NLD | ITA | GBR | FRA | ESP | DEU | CHE | BEL | AUT | AUS 1
NCT05186753 Phase II PLX9486 (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis Recruiting USA | POL | NOR | NLD | ITA | IRL | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BEL | AUT | AUS 0